Slingshot members are tracking this event:

Ignyta (RXDX) Secures Exclusive Global License to Lilly's (LLY) Oral Cancer Drug Candidate Taladegib for ~$53 Million plus an equity investment of $30mm in RXDX

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Management Comment This new targeted oncology program is a hedgehog/smoothened antagonist that complements our pipeline well and provides us with exciting potential monotherapy and combination therapy approaches across multiple solid tumor indications. We are grateful to Lilly for sharing Ignyta's precision oncology vision and recognizing the strong strategic fit of taladegib with our pipeline and capabilities, which led to its $30 million investment in the company.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Taladegib, Oral Cancer, Licensing